Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Endocrine/metabolic disease

Mitochondrial disease

Mammalian target of rapamycin (mTOR; FRAP; RAFT1)

Mouse studies suggest inhibiting mTOR with rapamycin could help treat Leigh's disease. In a mouse model of the mitochondrial disorder Leigh's disease, daily i.p. administration of 8 mg/kg rapamycin extended survival and delayed neurological symptoms, and also decreased both disease progression and neuroinflammation compared with vehicle. In the mouse model, rapamycin also decreased levels of glycolytic intermediates typically elevated in Leigh's syndrome compared with vehicle and induced a shift toward amino acid catabolism. Next steps include determining safety and efficacy of rapamycin or rapamycin analogs in young patients with Leigh's disease.

SciBX 7(1); doi:10.1038/scibx.2014.19
Published online Jan. 9, 2014

Unpatented; licensing status not applicable

Johnson, S.C. et al. Science; published online Nov. 14, 2013;
doi:10.1126/science.1244360
Contact: Matt Kaeberlein, University of Washington, Seattle, Wash.
e-mail:

kaeber@uw.edu